CA2946028C - Treatment of abnormal cutaneous scarring - Google Patents

Treatment of abnormal cutaneous scarring Download PDF

Info

Publication number
CA2946028C
CA2946028C CA2946028A CA2946028A CA2946028C CA 2946028 C CA2946028 C CA 2946028C CA 2946028 A CA2946028 A CA 2946028A CA 2946028 A CA2946028 A CA 2946028A CA 2946028 C CA2946028 C CA 2946028C
Authority
CA
Canada
Prior art keywords
apc
scar
skin
tgf
pathologic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2946028A
Other languages
English (en)
French (fr)
Other versions
CA2946028A1 (en
Inventor
Christopher John Jackson
Meilang Xue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ZZ Biotech LLC
Original Assignee
ZZ Biotech LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014901397A external-priority patent/AU2014901397A0/en
Application filed by ZZ Biotech LLC filed Critical ZZ Biotech LLC
Publication of CA2946028A1 publication Critical patent/CA2946028A1/en
Application granted granted Critical
Publication of CA2946028C publication Critical patent/CA2946028C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
CA2946028A 2014-04-16 2014-10-29 Treatment of abnormal cutaneous scarring Active CA2946028C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014901397A AU2014901397A0 (en) 2014-04-16 Treatment of abnormal cutaneous scarring
AU2014901397 2014-04-16
PCT/AU2014/050323 WO2015157791A1 (en) 2014-04-16 2014-10-29 Treatment of abnormal cutaneous scarring

Publications (2)

Publication Number Publication Date
CA2946028A1 CA2946028A1 (en) 2015-10-22
CA2946028C true CA2946028C (en) 2022-10-11

Family

ID=54323254

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2946028A Active CA2946028C (en) 2014-04-16 2014-10-29 Treatment of abnormal cutaneous scarring

Country Status (11)

Country Link
US (3) US20170042982A1 (enExample)
EP (1) EP3137102B1 (enExample)
JP (2) JP2017513944A (enExample)
CN (1) CN106573040B (enExample)
AU (1) AU2014391082B2 (enExample)
CA (1) CA2946028C (enExample)
DK (1) DK3137102T3 (enExample)
ES (1) ES2890675T3 (enExample)
PL (1) PL3137102T3 (enExample)
PT (1) PT3137102T (enExample)
WO (1) WO2015157791A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6273272B2 (ja) * 2012-07-04 2018-01-31 ジージー バイオテック エルエルシー 炎症性皮膚障害の治療
ES2890623T3 (es) 2014-04-16 2022-01-20 Zz Biotech Llc Uso del análogo de APC para curar heridas
WO2020191036A1 (en) * 2019-03-19 2020-09-24 Fibrogenesis Treatment of chronic obstructive pulmonary disease and lung degeneration using activated fibroblasts and exosome derivatives thereof
CN113073082A (zh) * 2021-03-19 2021-07-06 广州远想生物科技有限公司 TGF-β3间充质干细胞外泌体及其制备方法和应用
CN114788711A (zh) * 2022-04-26 2022-07-26 李娜 一种瘢痕评估方法及系统

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US4959318A (en) 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
EP0380508A4 (en) 1987-05-18 1991-04-03 Integrated Genetics, Inc. Improved protein c molecules and method for making and activating same
US5084274A (en) 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5093117A (en) 1989-01-24 1992-03-03 Baxter International Inc. Compositions and method for the treatment or prophylaxis of sepsis or septic shock
AT402260B (de) 1990-08-16 1997-03-25 Immuno Ag Protein c-hältige pharmazeutische präparation
US5571786A (en) 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
AT397615B (de) 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
WO1993009807A1 (en) 1991-11-18 1993-05-27 The Scripps Research Institute Methods of inhibiting thrombosis via elevation of circulating endogenous activated protein c levels
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4239150A1 (de) 1992-11-20 1994-05-26 Thomae Gmbh Dr K O-Acyl-4-phenyl-cyclohexanole, deren Salze, diese Verbindungen enthaltende Arzneimittel und deren Verwendung sowie Verfahren zu ihrer Herstellung
JP3043558B2 (ja) 1993-10-29 2000-05-22 財団法人化学及血清療法研究所 ヒト活性化プロテインｃ調製物及びその製法
WO1995030429A1 (en) 1994-05-04 1995-11-16 Board Of Trustees Of The University Of Arkansas Novel ophthalmologic uses of protein c
ZA983497B (en) 1997-04-28 1999-10-25 Lilly Co Eli Activated protein c formulations.
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
WO2001056532A2 (en) 2000-02-04 2001-08-09 The Scripps Research Institute Neuroprotective, antithrombotic and anti-inflammatory uses of activated protein c (apc)
WO2001059084A1 (en) 2000-02-11 2001-08-16 Eli Lilly And Company Protein c derivatives
WO2001072328A2 (en) * 2000-03-28 2001-10-04 Eli Lilly And Company Methods of treating diseases with activated protein c
AU1038802A (en) * 2000-10-18 2002-04-29 Maxygen Aps Protein c or activated protein c-like molecules
ATE550073T1 (de) * 2001-06-13 2012-04-15 Univ Sydney Protein c für die wundheilung
AU2003275948A1 (en) 2002-11-06 2004-06-07 Novo Nordisk A/S Pharmaceutical composition comprising a tissue factor antagonist and protein c polypeptides
ATE337003T1 (de) * 2003-04-28 2006-09-15 Biofrontera Bioscience Gmbh Verwendung von riluzole kombiniert mit geeigneten hilfs-und zusatzstoffen zur behandlung von krankheiten, die durch eine hyperproliferation von keratinozyten gekennzeichnet sind, insbesondere neurodermitis und psoriasis
US9192657B2 (en) 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
EP1651252B1 (en) * 2003-07-08 2014-11-26 The Scripps Research Institute Activated protein c variants with normal cytoprotective activity but reduced anticoagulant activity
US20070224150A1 (en) 2005-03-24 2007-09-27 Yongji Chung Growth factor for hair and skin treatment
ZA200800251B (en) * 2005-06-24 2009-04-29 Drugrecure Aps Airway administration of tissue factor pathway inhibitor in inflammatory conditions affecting the respiratory track
GR1005700B (el) 2006-09-01 2007-10-22 (40%) ����� �������� Τροπος αντιμετωπισης της 1ης φασης του εγκαυματοσσε μη σηπτικους ασθενεις με συνεχη ενδοφλεβια χορηγηση ενεργοποιημενης πρωτεινης-c για 48 ωρες με στοχο τη μειωση της τελικης εγκαυματικης βλαβης καιαυξηση της ταχυτητας επουλωσης κατα τα πρωτα επτα μετεγκαυματικα 24ωρα
EP2078074A4 (en) * 2006-10-31 2011-09-28 Scripps Research Inst DOSAGE SCHEME OF ACTIVATED PROTEIN C AND ITS VARIANTS WITH REDUCED ANTICOAGULANT ACTIVITY
GB0724231D0 (en) 2007-12-12 2008-01-30 Renono Ltd Methods for inhibiting scarring
ES2316312B1 (es) 2008-06-20 2010-02-08 Ignacio Umbert Millet Composicion farmaceutica dermatologica para el tratamiento de patologias de inflamacion de la piel, tales como por ejemplo dermatitis, dermatitis atopica, vitiligo, alopecia areata, acne, psoriasis y prurito,y combinaciones de las mismas.
EP2157176A1 (en) 2008-08-20 2010-02-24 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Protein C Variants
CN101912450A (zh) 2010-09-01 2010-12-15 吴业刚 一种治疗脚气皮炎的中西药组合物及其制备方法
JP6273272B2 (ja) * 2012-07-04 2018-01-31 ジージー バイオテック エルエルシー 炎症性皮膚障害の治療
ES2890623T3 (es) 2014-04-16 2022-01-20 Zz Biotech Llc Uso del análogo de APC para curar heridas

Also Published As

Publication number Publication date
PL3137102T3 (pl) 2022-02-07
US20200108128A1 (en) 2020-04-09
US20170042982A1 (en) 2017-02-16
US11491214B2 (en) 2022-11-08
EP3137102A4 (en) 2017-12-20
AU2014391082B2 (en) 2020-04-09
AU2014391082A1 (en) 2016-11-03
JP2020023519A (ja) 2020-02-13
PT3137102T (pt) 2021-09-28
EP3137102A1 (en) 2017-03-08
DK3137102T3 (da) 2021-10-11
CN106573040B (zh) 2021-07-06
EP3137102B1 (en) 2021-07-14
ES2890675T3 (es) 2022-01-21
CN106573040A (zh) 2017-04-19
WO2015157791A1 (en) 2015-10-22
CA2946028A1 (en) 2015-10-22
US20190060421A1 (en) 2019-02-28
JP6846063B2 (ja) 2021-03-24
JP2017513944A (ja) 2017-06-01

Similar Documents

Publication Publication Date Title
US11491214B2 (en) Treatment of abnormal cutaneous scarring
Medina et al. Pathophysiology of chronic nonhealing wounds
ES2676422T3 (es) Proteína C activada para su uso en el tratamiento de trastornos inflamatorios de la piel
Rogalski et al. Human leukocyte elastase induces keratinocyte proliferation in vitro and in vivo
US20100330028A1 (en) Combination therapy for chronic dermal ulcers
KR20220127880A (ko) 신경 손상 및 이의 관련 병증 치료 방법
AU2019343514B2 (en) Agent for treatment of dermatological disorders
US12214024B2 (en) Use of APC analogue for wound healing
Fife et al. Thrombin peptide Chrysalin® stimulates healing of diabetic foot ulcers in a placebo‐controlled phase I/II study
JP2004532892A6 (ja) 傷治癒のための処置および組成物
JP2023514819A (ja) 血圧異常症を予防及び治療する方法並びに薬剤
HK1235306B (en) Treatment of abnormal cutaneous scarring
HK1235306A1 (en) Treatment of abnormal cutaneous scarring
HK1230520A1 (en) Use of apc analogue for wound healing
HK1230520B (en) Use of apc analogue for wound healing
TW202228766A (zh) 一種治療神經損傷及其相關病症的方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190718

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241024

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241113

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 11TH ANNIV.) - STANDARD

Year of fee payment: 11

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251020

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251020